Ally Bridge Group

Tony Deng joined Ally Bridge Group in 2025 and is an Analyst for the public equity strategy focused on investments in therapeutics. Before joining Ally Bridge Group, Tony worked as a Vice President at Barclays in SMID-cap biotech equity research.

Ting Liu is an Analyst at Ally Bridge Group’s public equity strategy, focusing on therapeutics investments. She previously served as Director/Analyst at UBS and Senior Associate at RBC Capital Markets in Biotech Equity Research.

Srishti Kotiyal joined Ally Bridge Group in 2024 and is an Associate for the private equity strategy focused on investments in biotech. Before joining Ally Bridge Group, Srishti was an Associate in the Healthcare Investment Banking Group at Jefferies.

Slanix Paul Alex joined Ally Bridge Group in 2023 and is the Portfolio Manager and President for the public equity strategy. Before joining Ally Bridge Group, Slanix invested in life sciences companies as founding Partner and Senior Analyst for Tri Locum Partners.

Evan Zou joined Ally Bridge Group in 2022 and is a Senior Analyst for the public equity strategy focused on investments in therapeutics. Before joining Ally Bridge Group, Evan was an Associate Director on the Portfolio Intelligence team at BridgeBio Pharma.

Sam Brodovsky joined Ally Bridge Group in 2024 and is a Senior Associate for the private equity strategy focused on investments in medical technology. Prior to joining Ally Bridge Group, Sam was a Medical Device Equity Research Analyst at Truist Securities.

Stephen Mallon, PhD joined Ally Bridge Group in 2022 and is a Vice President for the private equity strategy focused on investments in therapeutics. Before joining Ally Bridge Group, Stephen was a Senior Research Associate at Royal Bank of Canada Capital Markets. Prior to that, Stephen was a Senior Research Associate at Chardan Capital Markets.

Andrew Lam joined Ally Bridge Group in 2021 and is a Managing Director, Head of Biotech, for the private equity strategy focused on investments in biotech. Before joining Ally Bridge Group, Andrew was Senior Director of Business Development at Intercept Pharmaceuticals. Before that, Andrew was a Vice President, Healthcare Investment Banking at Jefferies and an Equity Research Associate at BMO Capital and Canaccord Genuity. Andrew began his career at several biotechnology companies, including Celgene and Shire.

Jonathan Wang joined Ally Bridge Group in 2021 and is a Vice President for the private equity strategy. Before joining Ally Bridge Group, Jonathan worked as an Investment Manager at Navis Capital Partners. Before that, Jonathan worked in PricewaterhouseCoopers’ Transaction Services division.

Megan MacDonagh joined Ally Bridge Group in 2025 and is a Vice President for the private equity strategy focused on investments in medical devices and digital health. Before joining Ally Bridge Group, Megan was a Vice President at SV Health Investors, where she focused on early-stage and growth-stage medical device and digital health investments.

Carlos joined Ally Bridge Group in 2024 and is a Principal for the private equity strategy focused on investments in biotech. Before joining Ally Bridge, Carlos was in the investment teams at Section 32 and Pivotal bioVenture Partners focused on private biotech companies. Before his career in private equity, Carlos was in the BD and Corporate Strategy team at Ultragenyx and was a Senior Associate in the equity research teams at Deutsche Bank and Oppenheimer & Co.